CEO Meeting - Enlistment of Innovative Medicine in Hong Kong
HKAPI held its CEO Meeting, “Enlistment of Innovative Medicine in Hong Kong,” on 23 October 2026. The meeting brought together member company leaders, Board members, Task Force representatives, and external experts to discuss how Hong Kong can build a more transparent, structured, and value-based pathway for enlisting innovative medicines.
The meeting focused on two strategic priorities of HKAPI’s Enlistment Task Force: Innovative Funding Solutions, including risk-sharing agreements (RSAs) and managed entry agreements (MEAs), and Health Technology Assessment (HTA). Both areas are seen as important enablers of timely patient access while maintaining the sustainability of public healthcare funding.
Innovative Funding Solutions
Professor Manuel Antonio Espinoza, Associate Professor at the School of Public Health, The University of Hong Kong, shared an international perspective on the design of managed risk agreements. He explained how financial instruments, such as expenditure caps and rebate schemes, and outcome-based instruments, such as payment-by-results arrangements, can help payers and manufacturers manage uncertainty around cost, patient numbers, treatment duration, and clinical benefit.
Perspectives on HTA
The second session featured perspectives from local and international experts on the application of HTA in Hong Kong. Speakers included Professor Juliana Lui of The Chinese University of Hong Kong, Professor Manuel Espinoza of HKU, Dr Shirley Li of HKUMed, and Florence Lee, Co-Lead of HKAPI’s Enlistment Task Force.
Speakers discussed the importance of evidence generation, horizon scanning, real-world data, multi-criteria decision-making, and early engagement in supporting value assessment and reimbursement decisions. Professor Gilberto Leung, Convenor of the Institute for Medical Advancement and Clinical Excellence (IMACE), also joined a progressive conversation on how HTA could support sustainable healthcare in Hong Kong.
Looking Ahead
The meeting concluded with a shared commitment to continue building momentum on innovative funding solutions and HTA.
HKAPI will continue to work with members, the Government, HA, academia, and other stakeholders to advance a transparent, structured, and value-based enlistment pathway that supports timely access to innovative medicines for patients in Hong Kong.
